DEXIS to Showcase Cutting-Edge Innovations at IDS 2025
QUAKERTOWN, PENNSYLVANIA / ACCESS Newswire / March 24, 2025 / DEXIS, the global leader in dental imaging technologies, is excited to announce its participation in the International Dental Show (IDS) 2025 in Cologne, Germany.
The company will showcase new technologies within the DEXIS digital ecosystem, an AI-powered platform that connects each step of the digital workflow, from diagnosis to delivery. The ecosystem combines AI, 2D & 3D imaging, intraoral scanning, diagnostics, and treatment planning to create one integrated solution that streamlines processes and boosts productivity.
"We're excited to give IDS attendees the very first look at some of our new technologies," says DEXIS President, Robert Befidi. "All of our innovations are designed to improve patient interactions and make dental practices more effective and efficient. We're eager to put our products into the hands of dental professionals and demonstrate the capabilities of our new technologies."
Among these innovations are some exciting updates to the DEXIS intraoral scanning portfolio. Visitors will get an exclusive first look at the company's all-new intraoral scanner under development, Imprevo. With a sleek new design, fully rebuilt hardware, and AI-powered algorithm, Imprevo will become the new high-performance flagship of the DEXIS IOS portfolio.
IS ScanFlow, the software that powers the DEXIS intraoral scanner line, will preview its newest version, IS ScanFlow 2.0, featuring a new Smile Visualizer tool. The tool will allow dental professionals to show patients a realistic preview of their smile before and after treatments, helping them to visualize and better understand treatment recommendations.
DEXIS will also unveil updates to the ORTHOPANTOMOGRAPH™ OP 3D™ EX, which will soon include cephalometric imaging capabilities. The new ceph modality, which features the company's patented ORTHOceph™ Plus design, will provide necessary protocols such as lateral and pediatric lateral projections, posterior-anterior projections and carpus imaging* - all with fast scan times and at a limited dose.
Additionally, the DEXIS 3D imaging portfolio will introduce an Automatic Dose Control feature for the ORTHOPANTOMOGRAPH™ OP 3D™ LX. The feature will measure patients' anatomy and automatically set exposure levels for optimal image quality and dose. Early adopters have reported positive feedback:
"The new Automatic Dose Control is one of the few things in life I don't have to question," says Dr. Katya Archambault of San Diego Health Center. "It offers both better and more consistent image quality. I could never argue with the results."
Also being showcased are new features within DTX Studio™ Clinic, the core software of the DEXIS digital ecosystem. Known for its comprehensive integration of all modalities of patient data, DTX Studio Clinic streamlines diagnostics, patient education, treatment planning, and surgical guide generation.
The software's new features include a suite of tools designed to streamline the implant treatment planning process. Users can now plan an implant treatment and generate an automated surgical template chairside in under 3 minutes. Additionally, the software introduces an Assisted Implant Planning module that automates initial implant positioning, and a Face Scan tool that integrates facial scans with 3D X-rays, further enhancing the planning process.
Attendees will also get the chance to preview new innovations, set to be released in future updates of DTX Studio Clinic. Among these innovations is a new, AI-driven endodontic capability, that will provide 3D visualizations of root canals, enhancing diagnostic accuracy and treatment efficiency. Additionally, updates to the focus areas detection tool will be showcased, enhancing the visualization of teeth in intraoral X-rays and detecting eight additional dental findings.
DTX Studio Clinic will also introduce a new Cloud-based solution that will allow clinicians to connect their practices and consolidate data in one place. This feature is designed to enhance collaboration and streamline workflows, ultimately improving practice efficiency and patient outcomes. These advancements showcase the future of dental technology, making DTX Studio Clinic an integral part of modern dentistry.
DEXIS invites all IDS attendees to visit Hall 11.2 K050 L069 to experience the innovations that DEXIS has to offer. Their team of experts will be ready to provide demonstrations and answer questions.
With more than 165,000 solutions in use around the world, DEXIS continues to set the standard for quality and reliability in dental imaging. For more information about DEXIS and its participation in IDS, please visit DEXIS @ IDS 2025.
About DEXIS
DEXIS is the global leader in dental imaging. We bring together the most trusted brands in 2D and 3D imaging, intraoral scanning solutions, and diagnostic software, in one connected and AI-powered ecosystem. Our innovative and award-winning technologies use smart simplicity to increase productivity and enhance diagnostic confidence. For more information, please visit DEXIS.com.
About Envista
Envista Holdings Corporation is a global family of more than 30 trusted dental brands, including Nobel Biocare, Ormco, DEXIS, and Kerr, united by a shared purpose: to partner with professionals to improve lives. Envista helps its customers deliver the best possible patient care through industry-leading dental consumables, solutions, technology, and services. Its comprehensive portfolio, including dental implants and treatment options, orthodontics, and digital imaging technologies, covers a wide array of dentists' clinical needs for diagnosing, treating, and preventing dental conditions as well as improving the aesthetics of the human smile. With a foundation comprised of the proven Envista Business System (EBS) methodology, an experienced leadership team, and a strong culture grounded in continuous improvement, commitment to innovation, and deep customer focus, Envista is well equipped to meet the end-to-end needs of dental professionals worldwide. Envista is one of the largest global dental products companies, with significant market positions in some of the most attractive segments of the dental products industry. For more information, please visit www.envistaco.com.
DXIS01006/Rev00
*Carpus is an optional imaging program
Contact Information
Maria Penaloza
Media & Content Strategy Manager
mariap@accessnewswire.com
Michelle Cabral
Senior Marketing Director, DEXIS
michelle.cabral@envistaco.com
SOURCE: Envista
View the original press release on ACCESS Newswire
Envista
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Clean Air Metals Announces 2026 Strategic Objectives in Historically Strong PGE and Copper Markets13.1.2026 01:10:00 CET | Press release
THUNDER BAY, ON / ACCESS Newswire / January 12, 2026 / Clean Air Metals Inc. ("Clean Air Metals" or the "Company") (TSXV:AIR)(FRA:CKU0(OTCQB:CLRMF) is pleased to provide an overview of its 2026 objectives and highlights of 2025, for its 100%-owned Thunder Bay North ("TBN") Critical Minerals Project in Northwestern Ontario. Critical Project Advancement Objectives Spot prices for platinum, copper and palladium have appreciated by 70% (1000 $/oz), 25% (1.20 $/lb) and 50% 624($/oz) respectively versus study prices, since the results of the Preliminary Economic Assessment (PEA) were announced in the October 9th release. Using the financial model published in the PEA and applying current spot metal prices (as of January 6th), the TBN project shows a $708M1 NPV8 and a pre-tax IRR of 100% (post-tax NPV8 = $494M1 and IRR = 84%).This is a significant improvement in the project outlook in comparison to the PEA results that featured a $219.4M2 pre-tax NPV8 and a pre-tax IRR of 39%. This year, cons
Germany Buys Eight MQ-9B SeaGuardian(R) RPA Through NSPA12.1.2026 20:00:00 CET | Press release
NSPA Supports NATO Countries in the Acquisition and Sustainment of GA-ASI's Advanced Multi-Domain RPA SAN DIEGO, CALIFORNIA / ACCESS Newswire / January 12, 2026 / Germany's Federal Office of Bundeswehr Equipment, Information Technology and In-Service Support and the NATO Support and Procurement Agency (NSPA) have announced the procurement of eight MQ-9B SeaGuardian® Remotely Piloted Aircraft (RPA) from General Atomics Aeronautical Systems, Inc. (GA-ASI). The program includes four Certifiable Ground Control Stations. First delivery is expected in 2028. Germany joins a growing list of NATO countries that have selected GA-ASI's advanced MQ-9B RPA for its multi-domain capabilities with exceptionally long range and endurance. The platform provides pole-to-pole satellite control and de-icing capabilities to enable missions in cold climates. SeaGuardian features two multi-mode surface-search radars that deliver wide-area maritime surveillance, with an option to add Anti-Submarine Warfare capa
Datavault AI Announces Target to Expand its AI Driven Data Monetization Network to Over 100 Cities Across the Contiguous United States, Starting in the Second Half of 2026 with Corresponding 2027 Revenue Target12.1.2026 14:05:00 CET | Press release
Datavault AI expects to have a fully operational network with over 100 nodes across 33 cities nationwide, generating revenue in the second half of 2026. Target revenue for this project is $400 to $500 million, thereby supporting the $200 million revenue guidance for 2026. With the full deployment of Datavault AI's nodes across 100+ cities throughout the United States, the 2027 revenue target is $2.0 to $3.0 billion for 2027. New York and Philadelphia edge network activation positions Datavault AI to potentially capture a significant share of the insurance and financial sectors, the healthcare industry, and enterprise opportunities. PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 12, 2026 / Datavault AI Inc. (Nasdaq:DVLT), a leader in AI-driven data valuation, monetization, credentialing, and digital engagement technologies, today highlighted the strategic importance of its New York and Philadelphia edge network deployment with Available Infrastructure's SanQtum AI platform. This
OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC12.1.2026 13:00:00 CET | Press release
Successful Delivery of Commissioned ADC Candidate to Advance the Collaboration Between OBI and TegMine TAIPEI, TW / ACCESS Newswire / January 12, 2026 / OBI Pharma (4174.TWO) announced that it has entered into a commercial license agreement with TegMine Therapeutics, Inc. (TegMine), a San Francisco-based biopharma focused on developing antibodies targeting cancer-associated glycans and glycoproteins, for a glycan-targeting ADC. Under the terms of the agreement, OBI is eligible to receive an upfront payment as well as development and commercial milestones. Following product launch, OBI will also receive royalties based on a tiered percentage of annual net sales. While the detailed financial terms are not disclosed in accordance with the confidentiality provisions, the overall deal economics are broadly comparable to those of recent similar licensing transactions in the market. TegMine will obtain the exclusive global rights to develop and commercialize the ADC under the license agreemen
Charlie's Holdings (OTCQB:CHUC) Signs Agreement with IKE Tech to Commercialize Transformational Age-Gated Vapes that Will Address FDA Concerns Related to Youth Access12.1.2026 12:00:00 CET | Press release
SBX Product Line Will Feature First-Ever AI-Powered Blockchain-Based Age-Gating System for Vape Products IKE's patented biometric BLE Bluetooth chip and blockchain-based app will enable Charlie's to ensure that underage individuals will not be able to activate or utilize the Company's age-gated products. The IKE Licensing Agreement provides CHUC with a first mover advantage in youth access prevention (one of the FDA's top priorities) and a three-year exclusivity period for age-gated nicotine analogue products. Charlie's will test market the IKE age-gating system this spring with the Company's popular SBX nicotine analogue product line; simultaneously, Charlie's intends to incorporate the revolutionary technology into its PACHA branded Electronic Nicotine Delivery Systems (ENDS). COSTA MESA, CA / ACCESS Newswire / January 12, 2026 / Charlie's Holdings, Inc. (OTCQB:CHUC) ("Charlie's" or the "Company"), an industry leader in the premium vapor products space, today reported that the Compan
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom